From RAS inhibitor resistance to rational combination strategies -> https://www.nature.com/articles/s41591-026-04529-w

Anti-aging interventions need less hype and more clinical evidence -> https://www.nature.com/articles/s41591-026-04611-3

Reinventing health communication for the digital era -> https://www.nature.com/articles/s41591-026-04556-7

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer -> https://www.nature.com/articles/s41591-026-04537-w

Emergence of a Bundibugyo virus variant in the 2026 outbreak in the Democratic Republic of the Congo and Uganda -> https://www.nature.com/articles/s41591-026-04628-8

Editorial Expression of Concern: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis -> https://www.nature.com/articles/s41591-026-04620-2

Global access to different classes of diabetes medicines: a framework for targeted policy actions -> https://www.nature.com/articles/s41591-026-04579-0

Lessons from deploying the ChatEHR system at Stanford Medicine -> https://www.nature.com/articles/s41591-026-04574-5

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial -> https://www.nature.com/articles/s41591-026-04583-4

Decade-long persistence of CD19 CAR T cells in B cell lymphomas -> https://www.nature.com/articles/s41591-026-04578-1

Type 2 diabetes prevention across the life course -> https://www.nature.com/articles/s41591-026-04550-z

Large-scale whole-genome sequencing reveals the landscape and health implications of de novo mutations -> https://www.nature.com/articles/s41591-026-04585-2

A clinically validated framework for auditing AI chatbot behavior in mental health interactions -> https://www.nature.com/articles/s41591-026-04577-2